ID   STAT4_HUMAN             Reviewed;         748 AA.
AC   Q14765; Q96NZ6;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   28-JAN-2026, entry version 221.
DE   RecName: Full=Signal transducer and activator of transcription 4;
GN   Name=STAT4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Xu X., Sun Y.L., Hoey T.;
RT   "The STAT amino-terminal domain mediates cooperative DNA binding and
RT   confers selective sequence recognition.";
RL   Submitted (AUG-1996) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 91-748.
RG   SeattleSNPs variation discovery resource;
RL   Submitted (SEP-2001) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   FUNCTION, AND PHOSPHORYLATION.
RX   PubMed=7638186; DOI=10.1073/pnas.92.16.7307;
RA   Bacon C.M., Petricoin E.F. III, Ortaldo J.R., Rees R.C., Larner A.C.,
RA   Johnston J.A., O'Shea J.J.;
RT   "Interleukin 12 induces tyrosine phosphorylation and activation of STAT4 in
RT   human lymphocytes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:7307-7311(1995).
RN   [5]
RP   FUNCTION, AND PHOSPHORYLATION.
RX   PubMed=8943379;
RA   Cho S.S., Bacon C.M., Sudarshan C., Rees R.C., Finbloom D., Pine R.,
RA   O'Shea J.J.;
RT   "Activation of STAT4 by IL-12 and IFN-alpha: evidence for the involvement
RT   of ligand-induced tyrosine and serine phosphorylation.";
RL   J. Immunol. 157:4781-4789(1996).
RN   [6]
RP   INTERACTION WITH IL12RB2, AND FUNCTION.
RX   PubMed=10415122; DOI=10.1006/abbi.1999.1302;
RA   Yao B.B., Niu P., Surowy C.S., Faltynek C.R.;
RT   "Direct interaction of STAT4 with the IL-12 receptor.";
RL   Arch. Biochem. Biophys. 368:147-155(1999).
RN   [7]
RP   INTERACTION WITH IL12RB2.
RX   PubMed=9890938; DOI=10.1074/jbc.274.4.1875;
RA   Naeger L.K., McKinney J., Salvekar A., Hoey T.;
RT   "Identification of a STAT4 binding site in the interleukin-12 receptor
RT   required for signaling.";
RL   J. Biol. Chem. 274:1875-1878(1999).
RN   [8]
RP   FUNCTION, PHOSPHORYLATION AT TYR-693 AND SER-721, AND MUTAGENESIS OF
RP   TYR-693 AND SER-721.
RX   PubMed=10961885;
RA   Visconti R., Gadina M., Chiariello M., Chen E.H., Stancato L.F.,
RA   Gutkind J.S., O'Shea J.J.;
RT   "Importance of the MKK6/p38 pathway for interleukin-12-induced STAT4 serine
RT   phosphorylation and transcriptional activity.";
RL   Blood 96:1844-1852(2000).
RN   [9]
RP   FUNCTION.
RX   PubMed=11114383; DOI=10.1016/s1074-7613(00)00070-4;
RA   Oppmann B., Lesley R., Blom B., Timans J.C., Xu Y., Hunte B., Vega F.,
RA   Yu N., Wang J., Singh K.P., Zonin F., Vaisberg E., Churakova T., Liu M.-R.,
RA   Gorman D., Wagner J., Zurawski S., Liu Y.-J., Abrams J.S., Moore K.W.,
RA   Rennick D.M., de Waal-Malefyt R., Hannum C., Bazan J.F., Kastelein R.A.;
RT   "Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with
RT   biological activities similar as well as distinct from IL-12.";
RL   Immunity 13:715-725(2000).
RN   [10]
RP   FUNCTION, AND PHOSPHORYLATION AT SER-721.
RX   PubMed=12213961; DOI=10.1073/pnas.182618999;
RA   Morinobu A., Gadina M., Strober W., Visconti R., Fornace A., Montagna C.,
RA   Feldman G.M., Nishikomori R., O'Shea J.J.;
RT   "STAT4 serine phosphorylation is critical for IL-12-induced IFN-gamma
RT   production but not for cell proliferation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:12281-12286(2002).
RN   [11]
RP   INVOLVEMENT IN SLEB11.
RX   PubMed=19109131; DOI=10.4049/jimmunol.182.1.34;
RA   Kariuki S.N., Kirou K.A., MacDermott E.J., Barillas-Arias L., Crow M.K.,
RA   Niewold T.B.;
RT   "Cutting edge: autoimmune disease risk variant of STAT4 confers increased
RT   sensitivity to IFN-alpha in lupus patients in vivo.";
RL   J. Immunol. 182:34-38(2009).
RN   [12]
RP   FUNCTION.
RX   PubMed=26990433; DOI=10.1002/eji.201546050;
RA   Gonzales-van Horn S.R., Estrada L.D., van Oers N.S., Farrar J.D.;
RT   "STAT4-mediated transcriptional repression of the IL5 gene in human memory
RT   Th2 cells.";
RL   Eur. J. Immunol. 46:1504-1510(2016).
RN   [13]
RP   FUNCTION, AND INTERACTION WITH STAT1.
RX   PubMed=34508746; DOI=10.1016/j.yexcr.2021.112784;
RA   Li M., Liu Y., Fu Y., Gong R., Xia H., Huang X., Wu Y.;
RT   "Interleukin-35 inhibits lipopolysaccharide-induced endothelial cell
RT   activation by downregulating inflammation and apoptosis.";
RL   Exp. Cell Res. 407:112784-112784(2021).
RN   [14]
RP   FUNCTION, ACETYLATION AT LYS-667, AND SUBCELLULAR LOCATION.
RX   PubMed=35614130; DOI=10.1038/s41418-022-01017-9;
RA   Zhang Y.S., Xin D.E., Wang Z., Peng W., Zeng Y., Liang J., Xu M., Chen N.,
RA   Zhang J., Yue J., Cao M., Zhang C., Wang Y., Chang Z., Lu X.M., Chang L.,
RA   Chinn Y.E.;
RT   "Acetylation licenses Th1 cell polarization to constrain Listeria
RT   monocytogenes infection.";
RL   Cell Death Differ. 0:0-0(2022).
RN   [15]
RP   VARIANT [LARGE SCALE ANALYSIS] GLN-112.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [16]
RP   INVOLVEMENT IN SLEB11 AND RA.
RX   PubMed=17804842; DOI=10.1056/nejmoa073003;
RA   Remmers E.F., Plenge R.M., Lee A.T., Graham R.R., Hom G., Behrens T.W.,
RA   de Bakker P.I.W., Le J.M., Lee H.-S., Batliwalla F., Li W., Masters S.L.,
RA   Booty M.G., Carulli J.P., Padyukov L., Alfredsson L., Klareskog L.,
RA   Chen W.V., Amos C.I., Criswell L.A., Seldin M.F., Kastner D.L.,
RA   Gregersen P.K.;
RT   "STAT4 and the risk of rheumatoid arthritis and systemic lupus
RT   erythematosus.";
RL   N. Engl. J. Med. 357:977-986(2007).
RN   [17]
RP   INVOLVEMENT IN DPMC, VARIANTS DPMC TYR-623; VAL-635 AND ASP-650,
RP   CHARACTERIZATION OF VARIANTS DPMC TYR-623; VAL-635 AND ASP-650, MUTAGENESIS
RP   OF TYR-693, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=37256972; DOI=10.1056/nejmoa2202318;
RA   Baghdassarian H., Blackstone S.A., Clay O.S., Philips R.,
RA   Matthiasardottir B., Nehrebecky M., Hua V.K., McVicar R., Liu Y.,
RA   Tucker S.M., Randazzo D., Deuitch N., Rosenzweig S., Mark A., Sasik R.,
RA   Fisch K.M., Pimpale Chavan P., Eren E., Watts N.R., Ma C.A., Gadina M.,
RA   Schwartz D.M., Sanyal A., Werner G., Murdock D.R., Horita N., Chowdhury S.,
RA   Dimmock D., Jepsen K., Remmers E.F., Goldbach-Mansky R., Gahl W.A.,
RA   O'Shea J.J., Milner J.D., Lewis N.E., Chang J., Kastner D.L., Torok K.,
RA   Oda H., Putnam C.D., Broderick L.;
RT   "Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory
RT   Syndrome.";
RL   N. Engl. J. Med. 388:2241-2252(2023).
CC   -!- FUNCTION: Transcriptional regulator mainly expressed in hematopoietic
CC       cells that plays a critical role in cellular growth, differentiation
CC       and immune response (PubMed:10961885, PubMed:37256972, PubMed:8943379).
CC       Plays a key role in the differentiation of T-helper 1 cells and the
CC       production of interferon-gamma (PubMed:12213961, PubMed:35614130). Also
CC       participates in multiple neutrophil functions including chemotaxis and
CC       production of the neutrophil extracellular traps (By similarity). After
CC       IL12 binding to its receptor IL12RB2, STAT4 interacts with the
CC       intracellular domain of IL12RB2 and becomes tyrosine phosphorylated
CC       (PubMed:10415122, PubMed:7638186). Phosphorylated STAT4 then
CC       homodimerizes and migrates to the nucleus where it can recognize STAT
CC       target sequences present in IL12 responsive genes. Although IL12
CC       appears to be the predominant activating signal, STAT4 can also be
CC       phosphorylated and activated in response to IFN-gamma stimulation via
CC       JAK1 and TYK2 and in response to different interleukins including IL23,
CC       IL2 and IL35 (PubMed:11114383, PubMed:34508746). Transcription
CC       activation of IFN-gamma gene is mediated by interaction with JUN that
CC       forms a complex that efficiently interacts with the AP-1-related
CC       sequence of the IFN-gamma promoter (By similarity). In response to IFN-
CC       alpha/beta signaling, acts as a transcriptional repressor and
CC       suppresses IL5 and IL13 mRNA expression during response to T-cell
CC       receptor (TCR) activation (PubMed:26990433).
CC       {ECO:0000250|UniProtKB:P42228, ECO:0000269|PubMed:10415122,
CC       ECO:0000269|PubMed:10961885, ECO:0000269|PubMed:11114383,
CC       ECO:0000269|PubMed:12213961, ECO:0000269|PubMed:26990433,
CC       ECO:0000269|PubMed:34508746, ECO:0000269|PubMed:35614130,
CC       ECO:0000269|PubMed:37256972, ECO:0000269|PubMed:7638186,
CC       ECO:0000269|PubMed:8943379}.
CC   -!- SUBUNIT: Forms a homodimer or a heterodimer with a related family
CC       member. Interacts with ARL2BP (By similarity). The SH2 domain
CC       interacts, in vitro, with IL12RB2 via a short cytoplasmic domain.
CC       Interacts with STAT1 (PubMed:34508746). Interacts with JUN; this
CC       complex efficiently interacts with the AP-1-related sequence of the
CC       IFN-gamma (By similarity). {ECO:0000250, ECO:0000250|UniProtKB:P42228,
CC       ECO:0000269|PubMed:10415122, ECO:0000269|PubMed:34508746,
CC       ECO:0000269|PubMed:9890938}.
CC   -!- INTERACTION:
CC       Q14765; O14901: KLF11; NbExp=3; IntAct=EBI-1186538, EBI-948266;
CC       Q14765; O43504: LAMTOR5; NbExp=2; IntAct=EBI-1186538, EBI-713382;
CC       Q14765; Q9BVL2: NUP58; NbExp=3; IntAct=EBI-1186538, EBI-2811583;
CC       Q14765; Q14765: STAT4; NbExp=2; IntAct=EBI-1186538, EBI-1186538;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus {ECO:0000269|PubMed:35614130,
CC       ECO:0000269|PubMed:37256972}. Note=Translocated into the nucleus in
CC       response to phosphorylation. {ECO:0000269|PubMed:35614130}.
CC   -!- PTM: Acetylation at Lys-667 is required for JAK2-mediated
CC       phosphorylation and activation of STAT4. {ECO:0000269|PubMed:35614130}.
CC   -!- PTM: Tyrosine phosphorylated upon IL12 and IFN-alpha activation, but
CC       not by IFN-gamma in T-lymphocytes and NK cells (PubMed:8943379). Serine
CC       phosphorylation is required for maximal transcriptional activity but
CC       not for DNA binding (PubMed:8943379). Phosphorylation by MAP2K6 at Ser-
CC       721 is required for full transcriptional activity induced by IL12
CC       (PubMed:10961885). However this serine phosphorylation is not required
CC       for cell proliferation although critical for IFN-gamma production
CC       (PubMed:12213961). {ECO:0000269|PubMed:10961885,
CC       ECO:0000269|PubMed:12213961, ECO:0000269|PubMed:8943379}.
CC   -!- DISEASE: Systemic lupus erythematosus 11 (SLEB11) [MIM:612253]: A
CC       chronic, relapsing, inflammatory, and often febrile multisystemic
CC       disorder of connective tissue, characterized principally by involvement
CC       of the skin, joints, kidneys and serosal membranes. It is of unknown
CC       etiology, but is thought to represent a failure of the regulatory
CC       mechanisms of the autoimmune system. The disease is marked by a wide
CC       range of system dysfunctions, an elevated erythrocyte sedimentation
CC       rate, and the formation of LE cells in the blood or bone marrow.
CC       {ECO:0000269|PubMed:17804842, ECO:0000269|PubMed:19109131}.
CC       Note=Disease susceptibility is associated with variants affecting the
CC       gene represented in this entry.
CC   -!- DISEASE: Rheumatoid arthritis (RA) [MIM:180300]: An inflammatory
CC       disease with autoimmune features and a complex genetic component. It
CC       primarily affects the joints and is characterized by inflammatory
CC       changes in the synovial membranes and articular structures, widespread
CC       fibrinoid degeneration of the collagen fibers in mesenchymal tissues,
CC       and by atrophy and rarefaction of bony structures.
CC       {ECO:0000269|PubMed:17804842}. Note=Disease susceptibility is
CC       associated with variants affecting the gene represented in this entry.
CC   -!- DISEASE: Disabling pansclerotic morphea of childhood (DPMC)
CC       [MIM:620443]: An autosomal dominant, severe systemic inflammatory
CC       disorder that is part of the juvenile localized scleroderma spectrum.
CC       DPMC is characterized by poor wound healing with rapidly progressive
CC       deep fibrosis involving the mucous membranes, dermis, subcutaneous fat,
CC       fascia, muscles, and bone, leading to contractures, musculoskeletal
CC       atrophy, and articular ankylosis. Systemic manifestations include
CC       cytopenias and hypogammaglobulinemia, but scleroderma-associated
CC       autoantibodies are usually not present. The disorder is associated with
CC       high morbidity and mortality due to squamous-cell carcinoma,
CC       restrictive pulmonary disease, sepsis, and gangrene.
CC       {ECO:0000269|PubMed:37256972}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the transcription factor STAT family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; L78440; AAB05605.1; -; mRNA.
DR   EMBL; BC031212; AAH31212.1; -; mRNA.
DR   EMBL; AF423072; AAL12164.1; -; Genomic_DNA.
DR   CCDS; CCDS2310.1; -.
DR   RefSeq; NP_001230764.1; NM_001243835.2.
DR   RefSeq; NP_003142.1; NM_003151.4.
DR   RefSeq; XP_006712782.1; XM_006712719.4.
DR   RefSeq; XP_047301559.1; XM_047445603.1.
DR   RefSeq; XP_047301560.1; XM_047445604.1.
DR   RefSeq; XP_054199537.1; XM_054343562.1.
DR   RefSeq; XP_054199538.1; XM_054343563.1.
DR   RefSeq; XP_054199539.1; XM_054343564.1.
DR   RefSeq; XP_054199540.1; XM_054343565.1.
DR   RefSeq; XP_054199541.1; XM_054343566.1.
DR   AlphaFoldDB; Q14765; -.
DR   BMRB; Q14765; -.
DR   SMR; Q14765; -.
DR   BioGRID; 112652; 32.
DR   ComplexPortal; CPX-6042; STAT1/STAT4 complex.
DR   ComplexPortal; CPX-6046; STAT3/STAT4 complex.
DR   ComplexPortal; CPX-6050; STAT4 homodimer.
DR   DIP; DIP-39854N; -.
DR   FunCoup; Q14765; 1966.
DR   IntAct; Q14765; 47.
DR   MINT; Q14765; -.
DR   STRING; 9606.ENSP00000351255; -.
DR   BindingDB; Q14765; -.
DR   ChEMBL; CHEMBL4523296; -.
DR   GlyCosmos; Q14765; 3 sites, 1 glycan.
DR   GlyGen; Q14765; 3 sites, 1 O-linked glycan (3 sites).
DR   iPTMnet; Q14765; -.
DR   PhosphoSitePlus; Q14765; -.
DR   BioMuta; STAT4; -.
DR   DMDM; 6226158; -.
DR   CPTAC; CPTAC-1277; -.
DR   jPOST; Q14765; -.
DR   MassIVE; Q14765; -.
DR   PaxDb; 9606-ENSP00000376134; -.
DR   PeptideAtlas; Q14765; -.
DR   ProteomicsDB; 60158; -.
DR   ABCD; Q14765; 2 sequenced antibodies.
DR   Antibodypedia; 661; 1194 antibodies from 47 providers.
DR   DNASU; 6775; -.
DR   Ensembl; ENST00000358470.8; ENSP00000351255.4; ENSG00000138378.21.
DR   Ensembl; ENST00000392320.7; ENSP00000376134.2; ENSG00000138378.21.
DR   Ensembl; ENST00000432798.2; ENSP00000414322.2; ENSG00000138378.21.
DR   Ensembl; ENST00000450994.2; ENSP00000412397.2; ENSG00000138378.21.
DR   GeneID; 6775; -.
DR   KEGG; hsa:6775; -.
DR   MANE-Select; ENST00000392320.7; ENSP00000376134.2; NM_003151.4; NP_003142.1.
DR   UCSC; uc002usm.3; human.
DR   AGR; HGNC:11365; -.
DR   ClinPGx; PA36185; -.
DR   CTD; 6775; -.
DR   DisGeNET; 6775; -.
DR   GeneCards; STAT4; -.
DR   HGNC; HGNC:11365; STAT4.
DR   HPA; ENSG00000138378; Tissue enhanced (testis).
DR   MalaCards; STAT4; -.
DR   MIM; 180300; phenotype.
DR   MIM; 600558; gene.
DR   MIM; 612253; phenotype.
DR   MIM; 620443; phenotype.
DR   OpenTargets; ENSG00000138378; -.
DR   Orphanet; 117; Behcet disease.
DR   Orphanet; 85410; Oligoarticular juvenile idiopathic arthritis.
DR   Orphanet; 93552; Pediatric systemic lupus erythematosus.
DR   Orphanet; 85408; Rheumatoid factor-negative polyarticular juvenile idiopathic arthritis.
DR   Orphanet; 536; Systemic lupus erythematosus.
DR   VEuPathDB; HostDB:ENSG00000138378; -.
DR   eggNOG; KOG3667; Eukaryota.
DR   GeneTree; ENSGT01050000244905; -.
DR   HOGENOM; CLU_014189_3_0_1; -.
DR   InParanoid; Q14765; -.
DR   OMA; EGSHMVT; -.
DR   OrthoDB; 9511583at2759; -.
DR   PAN-GO; Q14765; 8 GO annotations based on evolutionary models.
DR   PhylomeDB; Q14765; -.
DR   PathwayCommons; Q14765; -.
DR   Reactome; R-HSA-8854691; Interleukin-20 family signaling.
DR   Reactome; R-HSA-8950505; Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation.
DR   Reactome; R-HSA-8984722; Interleukin-35 Signalling.
DR   Reactome; R-HSA-9020591; Interleukin-12 signaling.
DR   Reactome; R-HSA-9020933; Interleukin-23 signaling.
DR   Reactome; R-HSA-9020958; Interleukin-21 signaling.
DR   SignaLink; Q14765; -.
DR   SIGNOR; Q14765; -.
DR   Agora; ENSG00000138378; -.
DR   BioGRID-ORCS; 6775; 12 hits in 1179 CRISPR screens.
DR   ChiTaRS; STAT4; human.
DR   GeneWiki; STAT4; -.
DR   GenomeRNAi; 6775; -.
DR   Pharos; Q14765; Tchem.
DR   PRO; PR:Q14765; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   RNAct; Q14765; protein.
DR   Bgee; ENSG00000138378; Expressed in granulocyte and 123 other cell types or tissues.
DR   ExpressionAtlas; Q14765; baseline and differential.
DR   GO; GO:0005814; C:centriole; IDA:HPA.
DR   GO; GO:0000785; C:chromatin; ISA:NTNU_SB.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0016604; C:nuclear body; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProt.
DR   GO; GO:0090575; C:RNA polymerase II transcription regulator complex; IPI:ComplexPortal.
DR   GO; GO:0003700; F:DNA-binding transcription factor activity; IDA:UniProt.
DR   GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0000978; F:RNA polymerase II cis-regulatory region sequence-specific DNA binding; IBA:GO_Central.
DR   GO; GO:0007259; P:cell surface receptor signaling pathway via JAK-STAT; IBA:GO_Central.
DR   GO; GO:0019221; P:cytokine-mediated signaling pathway; IBA:GO_Central.
DR   GO; GO:0006952; P:defense response; IBA:GO_Central.
DR   GO; GO:0035722; P:interleukin-12-mediated signaling pathway; IDA:UniProt.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; NAS:ComplexPortal.
DR   GO; GO:0042127; P:regulation of cell population proliferation; IBA:GO_Central.
DR   GO; GO:0006357; P:regulation of transcription by RNA polymerase II; IBA:GO_Central.
DR   GO; GO:0070741; P:response to interleukin-6; IMP:UniProtKB.
DR   GO; GO:0043434; P:response to peptide hormone; IBA:GO_Central.
DR   GO; GO:0045063; P:T-helper 1 cell differentiation; IDA:UniProt.
DR   CDD; cd10375; SH2_STAT4; 1.
DR   CDD; cd16854; STAT4_CCD; 1.
DR   CDD; cd16848; STAT4_DBD; 1.
DR   FunFam; 1.10.238.10:FF:000012; Signal transducer and activator of transcription; 1.
DR   FunFam; 1.10.532.10:FF:000001; Signal transducer and activator of transcription; 1.
DR   FunFam; 1.20.1050.20:FF:000001; Signal transducer and activator of transcription; 1.
DR   FunFam; 3.30.505.10:FF:000003; Signal transducer and activator of transcription; 1.
DR   FunFam; 2.60.40.630:FF:000007; Signal transducer and activator of transcription 3; 1.
DR   FunFam; 2.60.40.630:FF:000008; signal transducer and activator of transcription 4; 1.
DR   Gene3D; 1.10.238.10; EF-hand; 1.
DR   Gene3D; 3.30.505.10; SH2 domain; 1.
DR   Gene3D; 1.20.1050.20; STAT transcription factor, all-alpha domain; 1.
DR   Gene3D; 2.60.40.630; STAT transcription factor, DNA-binding domain; 1.
DR   Gene3D; 1.10.532.10; STAT transcription factor, N-terminal domain; 1.
DR   InterPro; IPR008967; p53-like_TF_DNA-bd_sf.
DR   InterPro; IPR000980; SH2.
DR   InterPro; IPR036860; SH2_dom_sf.
DR   InterPro; IPR001217; STAT.
DR   InterPro; IPR046991; STAT4_CC.
DR   InterPro; IPR029839; STAT4_DBD.
DR   InterPro; IPR035856; STAT4_SH2.
DR   InterPro; IPR048988; STAT_linker.
DR   InterPro; IPR036535; STAT_N_sf.
DR   InterPro; IPR013800; STAT_TF_alpha.
DR   InterPro; IPR015988; STAT_TF_CC.
DR   InterPro; IPR013801; STAT_TF_DNA-bd.
DR   InterPro; IPR012345; STAT_TF_DNA-bd_N.
DR   InterPro; IPR013799; STAT_TF_prot_interaction.
DR   PANTHER; PTHR11801; SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION; 1.
DR   Pfam; PF00017; SH2; 1.
DR   Pfam; PF01017; STAT_alpha; 1.
DR   Pfam; PF02864; STAT_bind; 1.
DR   Pfam; PF02865; STAT_int; 1.
DR   Pfam; PF21354; STAT_linker; 1.
DR   SMART; SM00964; STAT_int; 1.
DR   SUPFAM; SSF49417; p53-like transcription factors; 1.
DR   SUPFAM; SSF55550; SH2 domain; 1.
DR   SUPFAM; SSF47655; STAT; 1.
DR   SUPFAM; SSF48092; Transcription factor STAT-4 N-domain; 1.
DR   PROSITE; PS50001; SH2; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Activator; Cytoplasm; Disease variant; DNA-binding; Nucleus;
KW   Phosphoprotein; Proteomics identification; Reference proteome; SH2 domain;
KW   Systemic lupus erythematosus; Transcription; Transcription regulation.
FT   CHAIN           1..748
FT                   /note="Signal transducer and activator of transcription 4"
FT                   /id="PRO_0000182420"
FT   DOMAIN          569..664
FT                   /note="SH2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00191"
FT   MOD_RES         667
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000269|PubMed:35614130"
FT   MOD_RES         693
FT                   /note="Phosphotyrosine; by JAK"
FT                   /evidence="ECO:0000269|PubMed:10961885"
FT   MOD_RES         721
FT                   /note="Phosphoserine; by MAP2K6"
FT                   /evidence="ECO:0000269|PubMed:10961885"
FT   VARIANT         112
FT                   /note="E -> Q (in a breast cancer sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036002"
FT   VARIANT         115
FT                   /note="I -> V (in dbSNP:rs3024839)"
FT                   /id="VAR_020190"
FT   VARIANT         584
FT                   /note="R -> W (in dbSNP:rs3024933)"
FT                   /id="VAR_047939"
FT   VARIANT         623
FT                   /note="H -> Y (in DPMC; likely pathogenic; increased
FT                   function in receptor signaling pathway via JAK-STAT)"
FT                   /evidence="ECO:0000269|PubMed:37256972"
FT                   /id="VAR_088806"
FT   VARIANT         635
FT                   /note="A -> V (in DPMC; likely pathogenic; increased
FT                   function in receptor signaling pathway via JAK-STAT)"
FT                   /evidence="ECO:0000269|PubMed:37256972"
FT                   /id="VAR_088807"
FT   VARIANT         650
FT                   /note="A -> D (in DPMC; likely pathogenic; increased
FT                   function in receptor signaling pathway via JAK-STAT)"
FT                   /evidence="ECO:0000269|PubMed:37256972"
FT                   /id="VAR_088808"
FT   MUTAGEN         693
FT                   /note="Y->A: Abrogates phosphorylation and transcriptional
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:10961885,
FT                   ECO:0000269|PubMed:37256972"
FT   MUTAGEN         721
FT                   /note="S->A: About 50% loss of transcriptional activity."
FT                   /evidence="ECO:0000269|PubMed:10961885"
FT   CONFLICT        365..371
FT                   /note="KNVSTLS -> N (in Ref. 3; AAL12164)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   748 AA;  85941 MW;  11E43803A9AF4FFA CRC64;
     MSQWNQVQQL EIKFLEQVDQ FYDDNFPMEI RHLLAQWIEN QDWEAASNNE TMATILLQNL
     LIQLDEQLGR VSKEKNLLLI HNLKRIRKVL QGKFHGNPMH VAVVISNCLR EERRILAAAN
     MPVQGPLEKS LQSSSVSERQ RNVEHKVAAI KNSVQMTEQD TKYLEDLQDE FDYRYKTIQT
     MDQSDKNSAM VNQEVLTLQE MLNSLDFKRK EALSKMTQII HETDLLMNTM LIEELQDWKR
     RQQIACIGGP LHNGLDQLQN CFTLLAESLF QLRRQLEKLE EQSTKMTYEG DPIPMQRTHM
     LERVTFLIYN LFKNSFVVER QPCMPTHPQR PLVLKTLIQF TVKLRLLIKL PELNYQVKVK
     ASIDKNVSTL SNRRFVLCGT NVKAMSIEES SNGSLSVEFR HLQPKEMKSS AGGKGNEGCH
     MVTEELHSIT FETQICLYGL TIDLETSSLP VVMISNVSQL PNAWASIIWY NVSTNDSQNL
     VFFNNPPPAT LSQLLEVMSW QFSSYVGRGL NSDQLHMLAE KLTVQSSYSD GHLTWAKFCK
     EHLPGKSFTF WTWLEAILDL IKKHILPLWI DGYVMGFVSK EKERLLLKDK MPGTFLLRFS
     ESHLGGITFT WVDHSESGEV RFHSVEPYNK GRLSALPFAD ILRDYKVIMA ENIPENPLKY
     LYPDIPKDKA FGKHYSSQPC EVSRPTERGD KGYVPSVFIP ISTIRSDSTE PHSPSDLLPM
     SPSVYAVLRE NLSPTTIETA MKSPYSAE
//
